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Abstract: Laparoscopic rectal cancer surgery has technical difficulties
with a higher complication rate than colon cancer. However, few studies
have examined whether postoperative complications are associated with
oncologic outcomes. The aim of this study is to evaluate the impact of
postoperative complications on long-term oncologic outcomes after
laparoscopic low anterior resection for rectal cancer.
Between January 2005 and December 2012, we evaluated 686
consecutive patients who underwent laparoscopic low anterior resection
for stage I-III rectal cancer. Patients were divided into complication
(n¼ 175) and noncomplication (n¼ 511) groups. The median follow-up
period was 38 months (range, 2–118). We compared perioperative
clinicopathologic outcomes, 5-year survival, and local recurrence
between groups and evaluated prognostic factors.
Five-year overall survival rates were 91.4% and 89.2% (P¼ 0.234)
and 5-year disease-free survival rates were 83.2% and 77.7%
(P¼ 0.002) in the noncomplication and complication groups for all
stages, respectively. For stage I cancer, both the 5-year overall survival
and the 5-year disease-free survival rate of the complication group were
lower than the noncomplication group. Local recurrence rates were
3.1% and 7.8% in the noncomplication and complication groups,
respectively (P¼ 0.002). In multivariate analysis, the presence of post-
operative complications was a significant predictor of 5-year disease-
free survival (hazard ratio, 1.65; P¼ 0.012).
Postoperative complications had a negative impact on 5-year dis-
ease-free survival after laparoscopic low anterior resection for rectal
cancer. The rate of local recurrence in the complication group increased
more than the noncomplication group. In particular, postoperative
complications were associated with poorer oncologic outcomes for
stage I cancer. Laparoscopic surgery is preferred for early-stage rectal
cancer so careful attention should be paid to avoid postoperativehD, Jeonghyun Ka Hur, MD,
MD, PhD, and Nam Kyu Kim, MD, PhD
Abbreviations: ASA = the American Society of Anesthesiologists,
BMI = body mass index, CG = complication group, CRM =
circumferential resection margin, GPS = Glasgow prognostic score,
HR = hazard ratio, LAR = low anterior resection, NCG = non-
complication group, POSSUM = Physiology and Operative
Severity Score for enUmeration of Mortality and morbidity, SIR
= systemic inflammatory response, TNM = tumor node metastasis.
INTRODUCTION
L aparoscopic surgery is regarded as a safe and feasibleprocedure for colorectal cancer. Randomized controlled trials
and meta-analyses comparing laparoscopic surgery with open
surgery have reported similar long-term oncologic outcomes for
the 2 procedures.1–5 However, laparoscopic surgery has been
reported to be associated with a shorter hospital stay, less pain,
and similar postoperative complication rates thanopen surgery.6,7
In addition, laparoscopic surgery is a technically advanced
procedure with features that include a magnified view, which
facilitates meticulous dissection in cases of rectal cancer surgery.
Laparoscopic surgery has been shown to be associated with
higher complication rates when performed for rectal cancer than
when performed for colon cancer because of technical diffi-
culties and anatomical limitations in the pelvic cavity. Accord-
ing to the results of the CLASICC trial, the complication rate for
rectal surgery was 13%, higher than the 7% rate for colon
surgery.8 In addition, the anastomotic leakage rate was higher
for rectal surgery (10.2%) than for colon surgery (2.3%;
P< 0.001).9 Furthermore, postoperative morbidities could
delay the administration of adjuvant therapy, increase hospital
stay, and reduce cost-effectiveness.10,11
Previous studies on laparoscopic rectal cancer surgery
focused on feasibility and safety in terms of oncologic outcomes
compared with those for open rectal cancer surgery. Few studies
have examined whether postoperative complications are associ-
ated with oncologic outcomes following laparoscopic colorectal
surgery. Therefore, we aimed to evaluate the impact of post-
operative complications on the long-term oncologic outcomes
after laparoscopic low anterior resection (LAR) for rectal cancer.
METHODS
Study Population and Data Collection
Between January 2005 and December 2012, 686 consecu-
tive patients underwent laparoscopic LAR for stage I-III rectal
cancer at Severance Hospital, Yonsei University College of
Medicine, Seoul, South Korea. Because the focus of this study
was the laparoscopic procedure, patients who underwent openexcluded. In addition, patients who had
oid tumors were not included. Patients
ominoperineal resection were also
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perineal wound could confound postoperative outcomes. Seven
patients who were lost to follow-up and 6 who died within 1
month after surgery (postoperative mortality cases) were
excluded. Finally, 686 patients were divided into 2 groups
according to the occurrence of postoperative complications:
the complication group (CG, n¼ 175) and the noncomplication
group (NCG, n¼ 511).
All data were collected from the Yonsei Colorectal Cancer
Database, and data completeness was ensured by electronic
medical chart review and telephone interviews. This study was
approved by the Institutional ReviewBoard of SeveranceHospital.
Evaluation Parameters
The patients were divided into 2 groups (CG and NCG) and
were evaluated for the following parameters: age, sex, weight,
height, body mass index (BMI), and the American Society of
Anesthesiologists (ASA) classification.
Tumor location was classified as low (5 cm), mid (5.1–
10 cm), or upper rectal (10.1–15 cm), according to the tumor’s
distance from the anal verge. Patients who had undergone
abdominal surgery before the rectal cancer surgery were con-
sidered to have a history of abdominal surgery.
The perioperative outcomes evaluated operation time and the
amount of intraoperative bleeding. Diverting ileostomy was per-
formed in patients with a high risk of postoperative leakage (male
patients with mid/low rectal cancer and patients who received
preoperative chemoradiotherapy), a positive air-leak test, or a
hand-sewn colo-anal anastomosis. The criterion for conversion
to open surgery was an unintended extension (by more than 4cm)
of the incisional site during surgery. Length of hospital stay was
FIGURE 1. Five-year overall survival rates: A, All stages; B, Stage Icalculated from the date of surgery to the date of discharge.
Pathologic outcomes were assessed according to the tumor
node metastasis (TNM) stage (American Joint Committee on
2 | www.md-journal.comCancer, seventh edition).12 On the basis of histologic findings,
tumors were considered to have a well, moderate, poor, or
mucinous differentiation. The surgical specimen was analyzed
to determine the number of harvested lymph nodes, lympho-
vascular invasion, and the circumferential resection margin
(CRM). CRM involvement was defined as the presence of
tumor cells within 1mm of the CRM.13 Tumor size, the
proximal resection margin, and the distal resection margin were
determined in the operating room, and pathologic reports were
reviewed to obtain additional information.
The oncologic outcomes were evaluated by overall survi-
val, disease-free survival, and local recurrence. Overall survival
was calculated from the date of surgery to the date of death.
Disease-free survival was calculated from the date of surgery to
the date of death or recurrence. Local recurrence was defined
when recurrence was observed at the primary site on radiologic
or histologic examination. Recurrence beyond the primary site
was considered to be distant metastasis. Five-year survival rates
were compared between the CG and NCG.
Postoperative Complications and Their Grading
Complications that occurred after surgery were considered
to be postoperative complications. These were classified
according to the Clavien-Dindo classification as summarized
in Table 3.14 In cases of multiple complications in a patient, the
one with the highest Clavien-Dindo classification was recorded
for analysis. We then compared oncologic outcomes between
patients with grade I-II complications and those with grade III-
IV complications (Figure 1).
Neoadjuvant Therapy and Postoperative
, Stage II; D, Stage III.Surveillance
Patients with T3/4 mid or low rectal cancer or positive
lymph nodes were treated with preoperative chemoradiotherapy
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.
TABLE 1. Patient Characteristics
Noncomplication Group (n¼ 511) Complication Group (n¼ 175) P
Age (years) 62.0 10.3 (28–87) 62.4 10.2 (31–89) 0.602
Sex 0.001y
Male 295 (57.7) 126 (72.0)
Female 216 (42.3) 49 (28.0)
Weight (kg) 61.1 9.5 (36–87) 63.7 10.6 (43–94) 0.003
Height (cm) 161.9 8.6 (140–184) 164.2 8.9 (135–182) 0.003
BMI (kg/m2) 23.3 3.0 (14.5–38.0) 23.6 3.3 (16.7–34.9) 0.234
ASA score 0.640y
1 215 (42.1) 67 (38.3)
2 282 (55.2) 102 (58.3)
3 14 (2.7) 6 (3.4)
Tumor location from anal verge 0.224y
Low (0–5 cm) 87 (17.0) 34 (19.4)
Mid (5.1–1 0cm) 276 (54.0) 102 (58.3)
High (10.1–15 cm) 148 (29.0) 39 (22.3)
History of abdominal surgery 0.029y
Yes 77 (15.1) 15 (8.6)
No 434 (84.9) 160 (91.4)
Preoperative chemoradiotherapy 0.086y
Yes 124 (24.3) 54 (30.9)
No 387 (75.7) 121 (69.1)
Continuous variables are described as mean standard deviation (range); categorical variables are described as n (%).
ASA¼American Society of Anesthesiologists, BMI¼ body mass index.
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fluorouracil or a capecitabine-based regimen). Surgery was
performed within 6 to 8 weeks after the completion of pre-
operative chemoradiotherapy. If preoperative chemoradiother-
apy was not possible, postoperative chemoradiotherapy
was administered.
Patients visited the outpatient clinic every 3 months there-
after for the first 2 years, and then, every 6 months until 5 years
postoperatively. Chest and abdominopelvic computed tomogra-
phy were performed every 6 months, and regular laboratory test
results, including those for carcinoembryonic antigen, were
examined at every visit. According to the National Compre-
hensive Cancer Network guidelines, all patients with stage III
rectal cancer and those with stage II cancer and high-risk factors
received 5-flourouracil based adjuvant chemotherapy.
Surgical Technique
Laparoscopic LAR was performed by high ligation of the
inferior mesenteric vessel, left colon mobilization, and splenic
flexure mobilization. Pelvic dissection was performed accord-
ing to the principles of total meseorectal excision.15 The
avascular plane between the presacral fascia and proper fascia
of the rectum was dissected. The specimen was extracted
through a mini-laparotomy, 3 to 4 cm from the trocar site in
the lower left quadrant area. After inserting an end-to-end
anastomosis (EEA) anvil into the proximal colon, intracorporeal
anastomosis between the proximal colon and distal rectum was
performed using the double-stapling method and hand-sewn
colo-anal anastomosis. For colo-anal anastomosis, dissection of

Student t test.
yChi-square test.the rectum was reached at the level of the dentate line. After
resecting the tumor, anastomosis between the anal canal at the
level of the dentate line and proximal colon was performed.
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.Statistical Analysis
Statistical analysis was performed with SPSS v. 20 for
Windows (SPSS Inc., Chicago, IL). Categorical variables were
analyzed using the Chi-square test or Fisher exact test. Con-
tinuous variables were analyzed using the Student t test. The 5-
year overall survival, 5-year disease-free survival, and local
recurrence rates were evaluated using the Kaplan-Meier
method. Comparisons of 5-year survival and local recurrence
between the CG and NCG were made using the log-rank test.
Univariate analysis to identify prognostic factors affecting 5-
year survival was performed using the log-rank test. Variables
found to be significant in univariate analysis were entered into
the Cox proportional hazards regression model for multivariate
analysis. A P value less than 0.05 was considered statistically
significant for all parameters.
RESULTS
Patient Characteristics
Patient characteristics were compared between the CG
and NCG. The proportion of men was higher in the CG than in
the NCG (72.0% vs 57.7%, P¼ 0.001). Height and weight
values were also higher in the CG than in the NCG. However,
BMI was not significantly different between the 2 groups
(P¼ 0.234). The rate of a history of abdominal surgery was
higher in the NCG (15.1%) than in the CG (8.6%; P¼ 0.029).
Age, the ASA score, and the administration of preoperative
chemoradiotherapy did not differ significantly between the
groups. The distributions of tumor location were not signifi-
cantly different (P¼ 0.224); mid-rectal cancers, located 5.1 to
10 cm from the anal verge, were the most common in both
groups (Table 1).
www.md-journal.com | 3
TABLE 2. Perioperative and Pathologic Outcomes
Noncomplication Group (n¼ 511) Complication Group (n¼ 175) P
Operation time (min) 250.9 82.2 (66–664) 292.8 177.5 (98–2270) 0.003
Intraoperative bleeding (mL) 124.4 210.9 (0–1550) 187.6 287.8 (0–2300) 0.008
Anastomotic type 0.132z
Double stapling method 464 (90.8) 150 (85.7)
Colo-anal J-pouch 5 (1.0) 2 (1.2)
Colo-anal-straight 42 (8.2) 23 (13.1)
Diverting ileostomy 0.463y
Yes 140 (27.4) 53 (30.3)
No 371 (72.6) 122 (69.7)
Conversion 0.011z
Yes 6 (1.2) 8 (4.6)
No 505 (98.8) 167 (95.4)
Length of hospital stay (days) 9.1 4.2 (4–49) 16.1 13.2 (5–92) <0.001
TNM stage 0.603y
I 226 (44.2) 70 (40.0)
II 129 (25.3) 49 (28.0)
III 156 (30.5) 56 (32.0)
Histologic differentiation 0.206z
Well 134 (26.2) 35 (20.0)
Moderate 358 (70.1) 137 (78.3)
Poor 7 (1.4) 1 (0.6)
Mucinous 12 (2.3) 2 (1.1)
Numbers of harvested lymph nodes 15.7 7.7 (3–49) 16.4 8.8 (3–49) 0.340
Tumor size (cm) 3.0 1.8 (0.1–11.2) 3.1 1.9 (0.1–10.0) 0.548
Proximal resection margin (cm) 12.2 5.0 (5.0–35.0) 12.5 4.9 (5.0–30.0) 0.427
Distal resection margin (cm) 2.6 1.9 (0.1–12.0) 2.4 1.5 (0.1–7.0) 0.110
Lymphovascular invasion 76 (14.9) 31 (17.7) 0.371y
CRM 0.182y
Noninvolved (>1mm) 480 (93.9) 169 (96.6)
Involved (1mm) 31 (6.1) 6 (3.4)
Continuous variables are described as mean standard deviation (range); categorical variables are described as n (%).
CRM¼ circumferential resection margin, TNM¼ tumor node metastasis.
Student t test.
yChi-square test.
z
Park et al Medicine  Volume 95, Number 14, April 2016Perioperative and Pathologic Outcomes
With respect to perioperative outcomes, operation time was
longer in the CG than in the NCG (292.8 177.5 vs
250.9 82.2min, P¼ 0.003). The amount of intraoperative bleed-
ing was greater in the CG than in the NCG (187.6 287.8 vs
124.4 210.9mL, P¼ 0.008). Conversion to open surgery was
significantly more frequent in the CG than in the NCG (4.6% vs
1.2%, P¼ 0.011). The length of hospital stay was longer in the CG
than in the NCG (16.1 13.2 vs 9.1 4.2 days, P< 0.001). How-
ever, anastomosis type and the rate of diverting ileostomy were not
significantly different between groups.
With respect to pathologic outcomes, there were no sig-
nificant differences for any of the parameters. The distributions
of TNM stage did not differ between the groups (P¼ 0.603).
Histologic differentiation, number of harvested lymph nodes,
tumor size, lymphovascular invasion, and proximal and distal
resection margins also did not differ significantly between the 2
Fisher exact test.groups. The rates of CRM involvement were 3.4% in the CG
and 6.1% in the NCG, but this difference was not significant
(P¼ 0.182), as summarized in Table 2.
4 | www.md-journal.comPostoperative Complications According to Their
Clavien-Dindo Classification
Postoperative complications according to their Clavien-
Dindo classification are listed in Table 3. The overall rate of
postoperative complications was 25.4%. Of these, 6.3% were
grade I complications. Voiding difficulty was the most common
complication (3.5% of the patients), and ejaculation dysfunction
was the second most common complication. In total, 2.6% of
the patients had grade II complications that included intestinal
obstruction (1.2%), ischemic colitis (0.3%), perianal abscess
(0.1%), wound infection (0.1%), and anastomotic leakage
(0.9%), which were treated by antibiotics. Overall, 1.7% of
the patients had grade IIIa complications, and anastomotic
stricture, which was treated by endoscopic balloon dilatation,
was the most common complication among these. The rate of
grade IIIb complications was 14.4%. Anastomotic leakage was
the most common grade IIIb complication (7.0%) and intestinal
obstruction was the second most common (3.1%). Nine patients
had rectovaginal fistulas and 1 had a rectovesical fistula. There
were 8 patients, who were treated by a diverting loop ileostomy
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.
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stricture. One patient with fecal incontinence underwent a
diverting ileostomy, and the complication was classified as
grade IIIb. Three patients had grade IV complications, which
included pneumonia, strangulation of the intestine, and stress-
induced cardiomyopathy.
Oncologic Outcomes in the CG and NCG
The mean follow-up period was 43.6 0.9 months (inter-
quartile range, 26–58 months), and the median follow-up
period was 38 months (range, 2–118 months). As shown in
Figure 2, the 5-year overall survival rate for all stages was not
significantly different in the CG and NCG (89.2% and 91.4%,
respectively; P¼ 0.234). However, for stage I cancer, the 5-year
overall survival rate was significantly higher in the NCG than in
the CG (98.4% vs 97.4%, P¼ 0.009). The proportions of
patients with stage II and III cancer were not significantly
different between the groups, as shown in Figure 2.
The 5-year disease-free survival rate for all stages was
significantly different between the CG and NCG as described in
Figure 3 (77.7% vs 83.2%; P¼ 0.002). In addition, for stage I
cancer, the 5-year disease-free survival rate was significantly
lower in the CG (83.8%) than in the NCG (92.7%, P< 0.001).
There were no significant differences between groups in the 5-
year disease-free survival rates for patients with stage II and III
cancer (Figure 3).
The cumulative incidence of local recurrence was higher in
the CG than in the NCG (7.8% vs 3.1%, P¼ 0.002), as shown in
Figure 4.
We compared oncologic outcomes between patients with
FIGURE 2. Five-year disease-free survival rates: A, All stages; B, Stgrade I-II complications and patients with grade III-IV com-
plications according to the Clavien-Dindo classification of
surgical complications, as described in Figure 1.14 The 5-year
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.disease-free survival rate among patients without postoperative
complications was 91.9%. Patients with postoperative compli-
cations had a lower 5-year disease-free survival, which was
91.5% for grade I-II complications and 72.1% for grade III-IV
complications (P< 0.001). However, 5-year overall survival
did not differ significantly according to the grade of
postoperative complications.
Prognostic Factors for the 5-year Survival Rate
In univariate analysis, age, conversion to open surgery,
TNM stage, histologic differentiation, number of harvested
lymph nodes, lymphovascular invasion, and postoperative com-
plications were prognostic factors for 5-year disease-free sur-
vival. With respect to 5-year overall survival, age, conversion to
open surgery, TNM stage, histologic differentiation, lympho-
vascular invasion, and CRM involvement were prognostic
factors (Table 4). Thus, age, conversion to open surgery,
TNM stage, histologic differentiation, and lymphovascular
invasion were the common prognostic factors for 5-year overall
survival and 5-year disease-free survival.
In multivariate analysis, TNM stage, number of harvested
lymph nodes, and postoperative complications were found to be
prognostic factors for 5-year disease-free survival. The hazard
ratio (HR) was lower for 12 harvested lymph nodes than for
<12 harvested lymph nodes (12 vs <12, HR, 0.52;
P¼ 0.001). The HR for 5-year disease-free survival was higher
in the CG than in the NCG (HR, 1.65; P¼ 0.012). The prog-
nostic factors for 5-year overall survival were age, TNM stage,
and histologic differentiation in multivariate analysis. TNM
stage was a common prognostic factor for 5-year disease-free
I; C, Stage II; D, Stage III.survival and 5-year overall survival. Compared with patients
with stage I cancer, the HR for disease-free survival among
patients with stage III rectal cancer was 3.88 (P< 0.001) and
www.md-journal.com | 5
TABLE 3. Details of Postoperative Complications
Postoperative Complications Case No. (%)
Grade I 43 (6.3%)
Voiding difficulty 24
Ejaculation dysfunction 9
Urinary frequency 5
Fecal incontinence 1
Dysuria 1
Wound seroma 1
Wound dehiscence 2
Grade II 18 (2.6%)
Intestinal obstruction 8
Ischemic colitis 2
Perianal abscess 1
Wound infection 1
Anastomotic leakage 6
Grade IIIa 12 (1.7%)
Anastomotic site stricture 7
Intestinal obstruction 3
Anastomotic site bleeding 1
Presacral abscess 1
Grade IIIb 99 (14.4%)
Anastomotic leakage 48
Anastomotic site stricture 8
Intestinal obstruction 21
Incisional hernia 7
Presacral abscess 2
Rectovaginal fistula 9
Rectovesical fistula 1
Vesicocutaneous fistula 1
Anastomotic site bleeding 1
Fecal incontinence 1
Grade IV 3 (0.4%)
Aspiration pneumonia 1
Park et al Medicine  Volume 95, Number 14, April 2016that for overall survival was 3.27 (P¼ 0.006). However, the
occurrence of postoperative complications was only the prog-
nostic factor for 5-year disease-free survival (Table 5).
DISCUSSION
In this study, we investigated whether postoperative com-
plications after laparoscopic LAR influence long-term oncolo-
gic outcomes in patients with rectal cancer. The most important
finding was that patients in the NCG with stage I cancer had
higher rates of both 5-year disease-free survival and overall
survival than those in the CG. In addition, although there was no
significant difference in the 5-year overall survival between the
CG and NCG for all stages (P¼ 0.234); the 5-year disease free
survival rate was higher and the local recurrence rate was lower
in the NCG than in the CG. The pathologic parameters related to
cancer behavior were not found to be confounding factors in the
interpretation of the present results, because there were no
significant differences between the CG and NCG in terms of
TNM stage, histologic differentiation, tumor size, resection
margins, lymphovascular invasion, and CRM involvement.
Oncologic outcomes were not significantly different
between the CG and NCG for patients with stage II and III
rectal cancer. These results suggest that postoperative compli-
cations did not influence oncologic outcomes in patients with
stage II or III rectal cancer. However, for stage I rectal cancer,
FIGURE 3. Cumulative incidence of local recurrence.oncologic outcomes were poorer in the CG than in the NCG.
Thus, in the early stages of rectal cancer, postoperative com-
plications may affect oncologic outcomes in the absence of
FIGURE 4. Five-year survival according to Clavien-Dindo classification
rate; B, Five-year overall survival rate.
6 | www.md-journal.compathologic tumor infiltration into perirectal fat or lymph node
metastasis. Meanwhile, the effect of postoperative compli-
cations on oncologic outcomes might be diluted in patients
with stage II-III rectal cancer because of the relatively higher
Strangulation of intestine 1
Stress-induced cardiomyopathy 1pathologic stage and tumor aggressiveness than in patients with
stage I rectal cancer. These results are supported by the fact that
excessive systemic inflammatory responses (SIRs) due to
of postoperative complications: A, Five-year disease-free survival
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.
TABLE 4. Prognostic Factors for 5-year Survivals by Univariate Analysis
No. (n¼ 686) DFS (%) P OVS (%) P
Age (years) 0.013 0.001
65 409 84.2 94.1
>65 277 78.1 85.7
Sex 0.284 0.364
Male 421 80.1 89.6
Female 265 84.3 92.7
BMI (kg/m2) 0.178 0.845
25 507 80.5 90.9
>25 179 85.1 90.6
ASA score 0.809 0.838
ASA 12 666 81.5 90.5
ASA 3 20 89.5 100.0
Tumor location from anal verge 0.400 0.070
Low (0–5 cm) 121 81.6 94.1
Mid (5.1–10 cm) 378 79.5 86.6
High (10.1–15 cm) 187 85.9 95.7
Preoperative chemoradiotherapy 0.750 0.307
Yes 178 84.3 95.6
No 508 81.2 89.9
Operation time (min) 0.500 0.938
265 393 83.6 90.7
>265 293 79.6 91.0
Anastomotic type 0.855 0.446
Double stapling method 614 81.8 90.2
Colo-anal J-pouch 7 80.0 100.0
Colo-anal-straight 65 83.0 95.5
Diverting ileostomy 0.495 0.776
Yes 193 77.2 89.0
No 493 83.1 91.0
Conversion 0.030 0.022
Yes 14 64.3 84.4
No 672 82.1 91.2
TNM stage <0.001 <0.001
I 296 90.4 98.1
II 178 83.1 89.0
III 212 68.3 83.0
Histologic differentiation <0.001 <0.001
Well 169 88.6 95.9
Moderate 495 80.4 90.1
Poor 8 62.5 32.8
Mucinous 14 65.5 72.9
Number of harvested lymph nodes 0.002 0.111
<12 211 73.9 88.4
12 475 85.9 92.1
Lymphovascular invasion 0.001 0.002
Yes 107 71.4 82.8
No 579 83.7 92.4
CRM 0.129 0.030
Noninvolved (>1mm) 649 82.3 91.1
Involved (1mm) 37 72.6 85.4
Postoperative complications 0.002 0.234
Yes 175 77.7 89.2
No 511 83.2 91.4
CRM¼ circumferential resection margin, DFS¼ disease-free survivals, OVS¼ overall survivals, TNM¼ tumor node metastasis.
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TABLE 5. Prognostic Factors for 5-year Survivals by Multivariate Analysis
Disease-free Survivals Overall Survivals
HR (95% CI) P

HR (95% CI) P

Age (years) 0.137 0.004
>65 vs 65 1.33 (0.91–1.94) 2.33 (1.31–4.14)
Conversion 0.051 0.069
Yes vs no 2.48 (1.00–6.18) 2.72 (0.93–8.01)
TNM stage <0.001 0.023
II vs I 1.81 (1.01–3.23) 0.046 2.13 (0.87–5.24) 0.099
III vs I 3.88 (2.31–6.50) <0.001 3.27 (1.39–7.67) 0.006
Histologic differentiation 0.162 0.012
Moderate vs well 1.62 (0.91–2.86) 0.101 1.97 (0.80–4.86) 0.141
Poor vs well 3.32 (0.93–11.89) 0.065 11.74 (2.66–51.72) 0.001
Mucinous vs well 2.34 (0.80–6.90) 0.122 2.58 (0.58–11.42) 0.211
Number of harvested lymph nodes 0.001
12 vs <12 0.52 (0.35–0.76)
Lymphovascular invasion 0.675 0.407
Yes vs no 1.10 (0.70–1.73) 1.32 (0.69–2.53)
CRM 0.608
Involved vs noninvolved 1.28 (0.50–3.29)
Postoperative complications 0.012
Yes vs no 1.65 (1.12–2.44)
tum
Park et al Medicine  Volume 95, Number 14, April 2016postoperative complications can influence oncologic outcomes.
Interestingly, there are several reports of inflammation-based
predictions of postoperative outcomes in patients with color-
ectal cancer.16–19 Ishuzuka et al asserted that the presence of a
SIR can be associated with poor oncologic outcomes, because
proinflammatory lymphocytes and hypercytokinemia, especi-
ally interleukin-6 level elevation, predispose the tumor to
further progression, invasion, and metastasis through immuno-
reactive processes.16,17 In addition, an elevated Glasgow prog-
nostic score (GPS), an inflammation-based prognostic score, is
associated with postoperative mortality.17 Thus, oncologic out-
comes are influenced not only by tumor-related pathologic
characteristics but also by SIR-related characteristics. Accord-
ingly, it is theoretically possible that SIR-related postoperative
complications affect oncologic outcomes in stage I rectal
cancer, which is less influenced by the pathologic factors of
the tumor. Currently, several indicators are used to predict
mortality in patients, such as the GPS or the Physiology and
Operative Severity Score for enUmeration of Mortality and
morbidity (POSSUM).16,20,21 We expect that these indicators
will be useful in providing a greater understanding of the effects
of surgical complications and their association with oncologic
outcomes after surgical procedures.
In this study, the occurrence of postoperative complications
was an independent prognostic factor for 5-year disease-free
survival. The results of a multivariate analysis showed that
postoperative complications had a 1.65 HR for 5-year disease-
free survival. In a previous study byLaw et al,10 the occurrence of
postoperative complications was an independent factor associ-
atedwith poor overall survival and a high tumor recurrence rate in
colorectal cancer. Because postoperative septic complications
CRM¼ circumferential resection margin, HR¼ hazard ratio, TNM¼
Cox proportional hazards regression model.and immunosuppression adversely affect outcomes after surgery,
the authors suggested that efforts to reduce postoperative com-
plications in colorectal cancer could improve oncologic
8 | www.md-journal.comoutcomes. Although our study focused on the outcomes of
laparoscopic LAR, the clinical importance of reducing post-
operative complications is consistent with the results of the study
by Law et al.10 Our results suggest that careful attention during
both surgery and postoperative management to avoid compli-
cations is crucial for favorable oncologic outcomes.
Patientswith grade III-IV postoperative complications had a
lower 5-year disease-free survival rate than those in the NCG and
those with grade I-II complications. Patients in the NCG, those
with grade I-II complications in the CG, and those with grade III-
IV complications in the CG were compared to assess oncologic
outcomes according to the severity of postoperative compli-
cations. In this study, the rate of anastomotic leakage was
7.0%, comparable with the 8 to 10% rates of anastomotic leakage
following laparoscopic procedures reported in previous stu-
dies.2,8 Because anastomotic leakage may lead to extraluminal
implantation of tumor cells, therewere concerns that it could have
a negative effect by diminishing survival through disease upsta-
ging as well as by increasing inflammatory responses, which
promote tumor spread.9,22,23 These findings suggest that surgeons
should pay special attention to performing careful surgical pro-
cedures in order to prevent postoperative complications.
This study has limitations because it was retrospective in
nature and conducted at a single institute. In addition, because
open rectal cancer surgeries were excluded, the understanding
about the oncologic effects of postoperative complications in
rectal cancer surgeries cannot be generalized. In a future study,
the impact of postoperative complications on oncologic out-
comes in patients undergoing all types of colorectal surgeries
should be investigated.
In conclusion, postoperative complications had a negative
or node metastasis.impact on 5-year disease-free survival after laparoscopic LAR
for rectal cancer. The rate of local recurrence in the CG
increased more than the NCG. In particular, for stage I cancer,
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.
patients with postoperative complications had poorer oncologic
outcomes. Because laparoscopic surgery is preferred in the early
stages of rectal cancer, these findings suggest that careful
attention is required to avoid postoperative complications fol-
lowing laparoscopic rectal cancer surgery because these could
negatively affect long-term oncologic outcomes. Further large-
scale, prospective randomized clinical trials are necessary to
confirm the present findings.
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